Last reviewed · How we verify

Tanvex BioPharma USA, Inc. — Portfolio Competitive Intelligence Brief

Tanvex BioPharma USA, Inc. pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
NYPOZI FILGRASTIM-TXID marketed Leukocyte Growth Factor [EPC] Specific cell surface receptors on hematopoietic cells Other
TX05 (trastuzumab) TX05 (trastuzumab) phase 3 HER2-targeted monoclonal antibody HER2 (human epidermal growth factor receptor 2) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Amgen · 1 shared drug class
  2. Berlex Labs · 1 shared drug class
  3. Biocon Biologics UK PLC · 1 shared drug class
  4. EVIVE BIOTECHNOLOGY · 1 shared drug class
  5. FRESENIUS KABI USA · 1 shared drug class
  6. Hoffmann-La Roche · 1 shared drug class
  7. KASHIV BIOSCIENCES LLC · 1 shared drug class
  8. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Tanvex BioPharma USA, Inc.:

Cite this brief

Drug Landscape (2026). Tanvex BioPharma USA, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tanvex-biopharma-usa-inc. Accessed 2026-05-17.

Related